Portfolio
Portfolio

Promedior

Pioneering the development of targeted therapeutics to treat diseases involving fibrosis.

Promedior is a clinical stage biopharmaceutical company developing a drug that addresses the most severe and difficult-to-treat fibrotic and inflammatory conditions. It has clinical programs in in the lung (IPF) and a form of fibrotic bone marrow cancer (myelofibrosis). In 2015 Promedior entered into a partnership giving Bristol-Myers Squibb the right to acquire the company at a total milestone based deal value is $1.25 billion.

Watch an interview with Dr. Srdan Verstovsek from MD Anderson at The Oncology TV Network on "PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks."

  • CEO Richard Jack (President and COO)
  • Industry Biotech